Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma: A phase h study

Acta Oncologica

Volumn 40, Issue 5, 2001, Pages 574-581

  El Weshi, A ^a   Khafaga, Y ^a   Allam, A ^a   Mosseri, V ^a   Ibrahim, E ^a   El Serafi, M ^a   El Badawi, S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

PATIENT TREATMENT; RADIOTHERAPY; TISSUE; TOXICITY; TUMORS;

SURVIVAL RATES;

CHEMOTHERAPY;

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOISOTOPE TELETHERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034803865     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418601750444105     Document Type: Article

References (38)

1. Carcinoma of the nasopharynx: Factors affecting prognosis
2. Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinomas evaluated by computer tomography
3. Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of local and regional control
4. Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma
5. Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of distant metastases and survival
6. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma
7. Radiation therapy and concurrent cisplatin in management of locoregionally advanced nasopharyngeal carcinomas
8. Pharynx
9. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma
10. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (≥N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival. VUMCA trial
11. Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Results of a matched cohort study
12. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099
13. Loss of local control with prolongation in radiotherapy
14. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
15. Randomized phase II clinical trials
16. Predicting distant failure in nasopharyngeal cancer
17. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx; a review of the Princess Margaret Hospital experience
18. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin and fluorouracil
19. High complete response in advanced nasopharyngeal carcinorma (UCNT) with bleomycin, epirubicin, and cisplatin before radiotherapy
20. Platinum based chemotherapy followed by radiation therapy of locally advanced nasopharyngeal cancer: A retrospective analysis of 39 cases
21. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma
22. Preliminary report of high dose epirubicin and cisplatin induction chemotherapy in locally advanced bulky undifferentiated carcinoma of nasopharyngeal type
23. Sequential chemotherapy and radiation for nasopharyngeal cancer: Absence of long-term benefit despite a high rate of tumor response to chemotherapy
24. Prognostic factors of nasopharyngeal carcinoma: A multivariate analysis
25. A retrospective study of the use of cisplatinum-5 fluorouracil neoadjuvant chemotherapy in cervical-node-positive nasopharyngeal carcinoma (NPC)
26. Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography
27. Combined radiotherapy and chemotherapy for nasopharyngeal carcinoma
28. Adjuvant chemotherapy with vincristine, cyclophosphamide and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: Results of a 4-year multicenter randomized study
29. Nasopharynx carcinoma: Choice of treatment
30. Accelerated hyperfractionation radiation therapy for carcinoma of the nasopharynx
31. Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma
32. Early tumor response and treatment toxicity after hyperfractionated radiotherapy in nasopharyngeal carcinoma
33. Brief summary of radiobiological principles in fractionated radiotherapy
34. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: Preliminary results of RTOG 9003
35. Overall time factor in postoperative radiation: Results of prospective randomized trial
36. Accelerated fractionation (AF) compared to conventional fractionation (CF) improved head and neck cancers: Results of the EORTC 22851 randomized trial
37. Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma
38. Repair halftimes estimated from observations of treatment-related morbidity after chart or conventional radiotherapy in head and neck cancer